Approval, commercialization and R&D risks in the active pharmaceutical ingredient and intermediate business
First written in FY2016. 9 of 20 entries say "Worsened", first in FY2019-Q2. Latest entry: 2026-11-02.
No other company in this theme has enough history to compare yet.
- FY2026WorsenedAnnual report
「The Pharmaceuticals segment reported lower revenue and lower profit due to a decline in sales volumes of contract-manufactured products.」
Pharmaceuticals segment revenue was ¥21.004 billion and the operating loss was ¥1.255 billion, reflecting the impact of lower sales volumes of contract-manufactured products on full-year results. - 2026-05-11WorsenedRevisions to earnings forecasts
「売上高及び営業利益は、機能品セグメント、樹脂・化成品セグメントなど全てのセグメントにおいて、主要製品の需要が想定に届かないことなどから、前回予想を下回る見込みです。」
医薬セグメントの売上高予想は230億円から210億円、営業利益予想は0億円から13億円の営業損失へ下方修正されました。 - FY2026-H1WorsenedAnnual report
「The Pharmaceuticals business reported lower revenue and lower profit due to a decline in sales volumes of contract-manufactured products. As a result, consolidated segment revenue was ¥10.476 billion, down ¥5.384 billion from the previous interim consolidated accounting period, while consolidated operating results deteriorated by ¥1.195 billion, resulting in a loss of ¥483 million.」
The Pharmaceuticals segment reported lower revenue and lower profit due to a decline in sales volumes of contract-manufactured pharmaceuticals, and turned to an operating loss. - FY2023-Q2MitigatedAnnual report
「The Pharmaceuticals business reported higher revenue as sales of proprietary and contract-manufactured pharmaceuticals remained firm.」
The business shifted from lower revenue caused by sluggish shipments of proprietary and contract-manufactured pharmaceuticals in the previous quarter, reporting higher revenue as sales in both businesses remained firm. - FY2023-Q1WorsenedAnnual report
「The Pharmaceuticals business reported lower revenue as shipments of proprietary and contract-manufactured pharmaceuticals were sluggish.」
Sluggish sales of proprietary pharmaceuticals were noted again following the previous quarter, and this time lower revenue resulted from sluggish shipments of both proprietary and contract-manufactured pharmaceuticals. - FY2022-Q3Firm royalty income and sluggish sales coexistedAnnual report
「The Pharmaceuticals business reported higher revenue but lower profit. Royalty income remained firm, but sales of proprietary pharmaceuticals were sluggish and other factors also weighed on results.」
While royalty income remained firm, the business reported higher revenue and lower profit due to sluggish sales of proprietary pharmaceuticals and other factors, indicating a change in earnings from the declining royalty income seen through the previous fiscal year. - FY2022-Q2MitigatedAnnual report
「The Pharmaceuticals business reported higher revenue and higher profit due to an increase in royalty income.」
The Pharmaceuticals business shifted from the deterioration in earnings caused by declining royalty income through the previous fiscal year, reporting higher revenue and higher profit due to an increase in royalty income. - FY2021-Q1WorsenedAnnual report
「The Pharmaceuticals business reported lower revenue and lower profit as shipments were sluggish for both proprietary and contract-manufactured pharmaceuticals compared with the same period of the previous year, when both had performed well.」
Unlike the strong sales in the same period of the previous year, shipments of both proprietary and contract-manufactured pharmaceuticals were sluggish this quarter, resulting in lower revenue and lower profit. - FY2020-Q3WorsenedAnnual report
「The Pharmaceuticals business reported higher revenue but lower profit. Sales by its pharmaceutical company customers remained strong for both proprietary and contract-manufactured pharmaceuticals, but royalty income declined.」
Although sales of proprietary and contract-manufactured pharmaceuticals remained strong, the business reported higher revenue and lower profit due to lower royalty income, representing a deterioration in earnings from the recovery noted in the previous quarter. - FY2020-Q2AdvancedAnnual report
「The Pharmaceuticals business reported higher revenue and higher profit as sales by its pharmaceutical company customers remained strong for both proprietary and contract-manufactured pharmaceuticals and royalty income increased.」
In addition to strong sales of proprietary and contract-manufactured pharmaceuticals, royalty income also increased, and the recovery in the Pharmaceuticals business continued to be reflected in higher revenue and higher profit. - FY2020-Q1Recovery in results driven by strong salesAnnual report
「The Pharmaceuticals business reported higher revenue and higher profit as sales by its pharmaceutical company customers remained strong for both proprietary and contract-manufactured pharmaceuticals.」
Unlike the previously reported lower revenue and lower profit caused by declining royalty income, the business reported higher revenue and higher profit this quarter due to strong sales of proprietary and contract-manufactured pharmaceuticals. As this does not refer to approval or commercialization risks themselves, it is recorded as a change in operating performance. - FY2019WorsenedAnnual report
「Sales volumes of contract-manufactured pharmaceuticals increased, and shipments of proprietary pharmaceuticals remained at approximately the level of the previous consolidated fiscal year, but royalty income declined following the expiry of the patent term for a proprietary pharmaceutical product.」
While sales volumes of contract-manufactured pharmaceuticals increased, the decline in royalty income due to patent expiry continued, and operating profit in the Pharmaceuticals segment fell 59.4% year on year to ¥855 million. - FY2019-Q3Higher contract-manufactured pharmaceutical sales and lower royalty income coexistedAnnual report
「The Pharmaceuticals business reported higher revenue but lower profit, as sales volumes of contract-manufactured pharmaceuticals increased while royalty income declined.」
Sales volumes of contract-manufactured pharmaceuticals increased, but the business reported higher revenue and lower profit due to lower royalty income, indicating a change in how earnings risks materialized in the Pharmaceuticals business. - FY2019-Q2WorsenedAnnual report
「The Pharmaceuticals business reported lower revenue and lower profit due to declines in royalty income from proprietary pharmaceuticals and in sales volumes.」
In addition to the decline in royalty income noted in the previous quarter, sales volumes also declined, and the Pharmaceuticals segment posted an operating loss of ¥4 million. - FY2019-Q1MaterialisedAnnual report
「The Pharmaceuticals business sold approximately the same volumes of proprietary and contract-manufactured pharmaceuticals as in the same cumulative period of the previous fiscal year, but reported lower revenue and lower profit due to a decline in royalty income.」
While pharmaceutical sales volumes were broadly in line with the previous year, the decline in royalty income materialized as lower revenue and lower profit. - FY2018MaterialisedAnnual report
「Royalty income declined following the expiry of the patent term for the company’s proprietary pharmaceutical product.」
The decline in royalty income due to the expiry of a pharmaceutical patent actually occurred, and operating profit in the Pharmaceuticals segment fell 15.6% year on year. - FY2016First statedAnnual report
「It may take pharmaceutical companies a long time to obtain manufacturing approval from the authorities, and they may be unable to commercialize their products. Even after contract manufacturing has been undertaken, approval may be revoked due to side effects or other factors, or full-scale commercialization may be delayed.」
The success or failure of approval, commercialization and research and development was identified as a risk for both the contract manufacturing and drug discovery businesses.